Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 1/20 | 0.33 |
| ▸ | HTR2C | P28335 | 4/20 | 0.32 |
| ▸ | HTR2B | P41595 | 4/20 | 0.32 |
| ▸ | HTR2A | P28223 | 3/20 | 0.32 |
| ▸ | HTR1A | P08908 | 3/20 | 0.32 |
| ▸ | HTR6 | P50406 | 2/20 | 0.32 |
| ▸ | HTR4 | Q13639 | 2/20 | 0.32 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.32 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.32 |
| ▸ | HTR1B | P28222 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | HTR1D | P28221 | 1/20 | 0.32 |
| ▸ | HTR7 | P34969 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29736506 | 1.00 | PTGS2 (0.33) | PTGS2HTR2CHTR2BHTR2AHTR1A | |
| Hydrochloric Acid SCHEMBL29736398 | 0.99 | ALDH1A1 (0.34) | PTGS2HTR2CHTR2BHTR2AHTR1A | |
| Hydrochloric Acid SCHEMBL28588530 | 0.99 | ALDH1A1 (0.34) | PTGS2HTR2CHTR2BHTR2AHTR1A | |
| SCHEMBL29736486 | 0.92 | HTR2C (0.34) | PTGS2HTR2CHTR2BHTR2AHTR1A | |
| SCHEMBL21954938 | 0.86 | USP2 (0.36) | ALDH1A1 | |
| SCHEMBL21954939 | 0.86 | USP2 (0.36) | ALDH1A1 | |
| Hydrochloric Acid SCHEMBL21955058 | 0.85 | PKM (0.35) | ALDH1A1 | |
| Hydrochloric Acid SCHEMBL21955059 | 0.85 | PKM (0.35) | ALDH1A1 | |
| SCHEMBL29736282 | 0.84 | MEN1 (0.36) | PTGS2ALDH1A1 | |
| SCHEMBL22017092 | 0.82 | PTGS2 (0.32) | PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11224600-B2 | Compounds for inhibition of alpha 4 beta 7 integrin | GILEAD SCIENCES, INC. (US) | 2022-01-18 | — | — | US | disclosed |
| US-20200155563-A1 | COMPOUNDS FOR INHIBITION OF ALPHA 4 BETA 7 INTEGRIN | GILEAD SCIENCES, INC. | 2020-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200155563-A1 | COMPOUNDS FOR INHIBITION OF ALPHA 4 BETA 7 INTEGRIN | ITGB7, ITGB4, ITGA4 | PTGS2 2563/4885HTR2C 4303/4885HTR2B 2861/4885 |
| US-11224600-B2 | Compounds for inhibition of alpha 4 beta 7 integrin | ITGB7, ITGB4, ITGA4 | PTGS2 2563/4885HTR2C 4303/4885HTR2B 2861/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.